S. Garciaz

发表

Acute Immune Hematological Complication of Oxaliplatin. A Series of 3 Cases

J. Raoul, P. Ries, S. Oziel-Taieb, 2014, Tumori.

Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma

R. Bouabdallah, B. Chetaille, D. Blaise, 2014, Hematological oncology.

Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC

R. Bouabdallah, L. Biard, G. Socié, 2019, Leukemia & lymphoma.

Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients

R. Bouabdallah, B. Chetaille, B. Esterni, 2014, Leukemia & lymphoma.

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study

R. Houot, L. Fornecker, R. Gressin, 2022, Bone Marrow Transplantation.

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

R. Houot, R. Bouabdallah, L. Fornecker, 2020, Bone Marrow Transplantation.

Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses.

S. Dawson, M. Dawson, A. Wei, 2022, Cancer cell.

Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity

R. Bouabdallah, L. Xerri, D. Blaise, 2016, Bone Marrow Transplantation.

Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas

O. Dereure, S. Dalle, M. Beylot-Barry, 2014, Haematologica.

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

J. Rey, N. Vey, V. Maisano, 2022, Cancers.

Primary dediffentiated liposarcoma of the dura mater: case report

S. Salas, C. Bouvier, P. Roche, 2012, Acta Neurochirurgica.

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

B. Pégourié, P. Moreau, X. Leleu, 2013, Leukemia.

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

R. Bouabdallah, A. Santoro, D. Blaise, 2015, Haematologica.

Letter to the editor: Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.

F. Pasquier, F. Rosselli, S. de Botton, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Contiguous follicular lymphoma and follicular lymphoma in situ harboring N-glycosylated sites

B. Nadel, L. Xerri, E. Mamessier, 2015, Haematologica.

Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF

D. Blaise, J. Chiaroni, C. Chabannon, 2020, PloS one.

Lower Relapse and Better PFS Among Chemosensitive Patients Undergoing Allogeneic Transplantation By Haploidentical Compared With HLA-Identical DONOR: Results On A Cohort Of 94 Patients With Hodgkin’S Lymphoma

R. Bouabdallah, A. Santoro, D. Blaise, 2013 .

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

L. Obéric, L. Ysebaert, T. Filleron, 2018, American journal of hematology.

Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers

R. Houot, I. Yakoub-Agha, L. Fornecker, 2018, American journal of hematology.

Regulation of the positive transcriptional effect of PLZF through a non-canonical EZH2 activity

C. Guillouf, J. Andrau, A. Saurin, 2018, Nucleic acids research.

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance

N. Vey, C. Saillard, Y. Hicheri, 2021, Cancers.

Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation

F. Bertucci, D. Birnbaum, P. Finetti, 2019, Clinical Epigenetics.

Clinical and biological aspects of aggressive B-cell non-Hodgkin lymphoma in adolescents and young adults

R. Bouabdallah, D. Coso, S. Garciaz, 2015 .

Lenalidomide for the treatment of B-cell lymphoma

R. Bouabdallah, D. Coso, S. Garciaz, 2016, Expert opinion on investigational drugs.

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death

S. Dawson, K. Brown, M. Dawson, 2021, Cancer discovery.

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

M. Jongen‐Lavrencic, A. Wei, S. de Botton, 2022, Blood.

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile

M. Hospital, S. Garciaz, 2023, OncoTargets and therapy.

IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

M. Béné, C. Récher, J. Rey, 2020 .

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

B. Pégourié, P. Moreau, X. Leleu, 2014, Journal of Cancer.

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available

R. Bouabdallah, D. Blaise, D. Coso, 2015, Bone Marrow Transplantation.

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available

R. Bouabdallah, D. Blaise, D. Coso, 2015, Bone Marrow Transplantation.

Erratum: Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available (Bone Marrow Transplantation (2015) 50 (865-867) DOI: 10.1038/bmt.2015.22)

R. Bouabdallah, D. Blaise, D. Coso, 2015 .

Targeting regulated cell death pathways in acute myeloid leukemia

N. Vey, Y. Collette, T. Miller, 2023, Cancer drug resistance.

Rituximab‐ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy

R. Bouabdallah, P. Brice, C. Thieblemont, 2016, British journal of haematology.

H. Dombret, P. Fenaux, S. Thépot, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

F. Pasquier, C. Guillouf, F. Rosselli, 2020 .

Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers

L. Obéric, L. Ysebaert, T. Filleron, 2017 .

F. Pasquier, F. Rosselli, S. de Botton, 2021, Annals of Oncology.

Erythroleukemia: Classification

D. Birnbaum, N. Cervera, N. Vey, 2023, eJHaem.

Caspase-2 protects against ferroptotic cell death

Laura F. Dagley, Sharad Kumar, W. Phillips, 2023, bioRxiv.